1315P Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer)
| Autor: | Felip, E., Lim, F.L., Johnson, M., O'Brien, M., Barlesi, F., Mazieres, J., Solomon, B., Moreno, V., Boni, V., Swalduz, A., Goldberg, S., Keam, B., Allen, S., Helms, H-J., Shemesh, C., Pintoffl, J., Al-Sakaff, N., Bailey, L., Sayyed, P., Cho, B.C. |
|---|---|
| Zdroj: | In Annals of Oncology September 2020 31 Supplement 4:S850-S850 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|